Skip to content

Effects of Antioxidant Sugar vs Granulated Sugar on Metabolic Outcomes in Healthy and Cardio Metabolic Subjects

1: Effects of Antioxidant-rich Sugar as Alternative Compared to Granulated Sugar on Gene Expression and Other Metabolic Parameters in Healthy Subjects 2: Effectiveness of Education Module to Modify Sugar Consumption Among Individuals With Cardio Metabolic Risk

Status
Terminated
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04737044
Acronym
MSS
Enrollment
50
Registered
2021-02-03
Start date
2022-02-01
Completion date
2022-07-01
Last updated
2023-02-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cardiometabolic Risk, Gene Expression, Metabolic Syndrome

Keywords

Antioxidant sugar, Gene Expression, Cardio metabolic risks, Education tool

Brief summary

Study 1: To investigate the effects of antioxidant-rich sugar as alternative compared to granulated sugar on gene expression and other metabolic parameters in healthy subjects. The hypotheses is antioxidant-rich sugar have positive effects on reducing inflammatory cytokines, oxidative stress biomarkers and other metabolic parameters in intervention group compared to control group. Study 2: To evaluate the effectiveness of a nutrition education module in modifying sugar consumption and other CMR-related outcomes in individuals with cardiometabolic risk. The hypotheses is the nutrition education module significantly improves the sugar consumption and other CMR-related outcomes in the intervention groups compared to the control group

Detailed description

Study 1: After being informed about the study and potential risks, written informed consent will be obtained from all subjects involved in the study. Respondents will be interviewed at Nutritional Status Assessments Lab at University of Putra, Malaysia (UPM) to obtain socio-demographic data, medical status, nutritional status, lifestyle practices and daily dietary intake. This study will be conducted for a period of 8 weeks. The study design is single-blinded parallel-randomized controlled trial (n=80), with 40 subjects in each group (one intervention and one control group). The participants will be selected based on the inclusion and exclusion criteria. Study 2: After being informed about the study and potential risks, written informed consent will be obtained from all subjects involved in the study prior to commencing the study. Respondents will be screened at Nutritional Status Assessments Lab at UPM for mental health status, daily sugar intake, cardiometabolic risk factors (waist circumference, blood pressure, fasting blood glucose, triglyceride and high-density lipoprotein cholesterol) where blood pressure and blood sample will be taken by the phlebotomist. Female candidates will be screened for pregnancy or breast feeding. Those who meet the inclusion/exclusion criteria will be selected. They will be informed via communication application whether they are eligible for the study. This study will be conducted for a period of 6 months.

Interventions

OTHERStudy 1: MRBS

MRBS as added sugar based on their habitual diet

OTHERStudy 2: White sugar & education module

White sugar for daily usage (\<10% daily energy intake)

OTHERStudy 2: MRBS & education module

MRBS for daily usage (\<10% daily energy intake)

Sponsors

Central Sugars Refinery Sdn Bhd, Malaysia
CollaboratorUNKNOWN
Universiti Putra Malaysia
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER
Masking
SINGLE (Subject)

Intervention model description

Study 1: The study will be using a two-arm single-blinded RCT with 40 subjects in each of the intervention and control groups. Study 2: The study will be using a three-arm RCT with 23 subjects in each groups (two interventions and one control groups).

Eligibility

Sex/Gender
ALL
Age
18 Years to 59 Years
Healthy volunteers
Yes

Inclusion criteria

Study 1: Inclusion Criteria: * Willingness to adhere to study protocol * Healthy adults to be aged between 18 and 60 years in both genders * Being non-smoker * Body mass index (BMI) between 23 - 26.9 kg/m2 (overweight).

Exclusion criteria

* Present of any kidney, liver and/or inflammatory disease (inflammatory bowel disease, Rheumatoid arthritis and etc.), thyroid disorder, diabetes (Type 1 & Type 2), cardiovascular or metabolic disease * Individuals with impaired glucose tolerance or with fasting blood glucose level that more than 5.2 mmol/L * Pregnancy or lactation * Alcohol consumption, food allergy * Individuals who are on regular antioxidant, anti-inflammatory and /or anti-obesity drugs, receiving any glucose lowering and/or lipid lowering medications * Change in the diet and physical activity (significant weight changes during study period) * Subjects who habitually consumed beverages rich in sugar such as milo, Teh tarik more than 500 ml, (as tested with the FFQ) Study 2: Candidates will be screened for: * Cardiometabolic risk factors (waist circumference, blood pressure, fasting blood glucose, triglyceride and high-density lipoprotein cholesterol) * Pregnancy or breast feeding * Mental health status * Daily total sugar intake Inclusion Criteria: * Malaysian, aged ≥18-59 years old * Able to read, write and communicate well either in Malay or English * Attained at least formal education level (secondary school and above) * Able to use the gadgets and have access to the internet * Presence with Cardiometabolic risk defines at least any of three out of five risk factors are present and the risk factors are:waist circumference (men: ≥90cm, women:≥80 cm); blood pressure (≥130/85 mmHg); having diabetes mellitus or fasting blood sugar (≥5.6mmol/L); triglyceride (≥1.7 mmol/L) or high-density lipoprotein (men: \<1.03 mmol/L, women: \<1.3 mmol/L). * Daily free sugar intake ≥10% of the daily energy intake

Design outcomes

Primary

MeasureTime frameDescription
Study 1: Gene expression of inflammation biomarkers (interleukin-6)8 weeksChange from baseline in gene expression of interleukin-6 in micrograms at 8th weeks.
Study 1: Gene expression of inflammation biomarkers (TNF-α)8 weeksChange from baseline in gene expression of TNF-α in picograms per milliliter at 8th weeks.
Study 1: Gene expression of inflammation biomarkers (CPR)8 weeksChange from baseline in gene expression of CPR in milligram per liter at 8th weeks.
Study 1: Gene expression of oxidative stress biomarkers (MDA)8 weeksChange from baseline in gene expression of MDA in millimolar at 8th weeks.
Study 1: Gene expression of oxidative stress biomarkers (SOD)8 weeksChange from baseline in gene expression of SOD in Units per milliliter at 8th weeks.
Study 1: Gene expression of oxidative stress biomarkers (CAT)8 weeksChange from baseline in gene expression of CAT in nanomoles at 8th weeks.
Study 2: Change from baseline in sugar consumption3 monthsDietary sugar intake will be determined using a 3-day food record and semi-quantitative FFQ of added sugar intake. Total sugar (grams per day) in foods will be calculated using formula \[(total sugar (grams) - natural sugar (grams)\]. The total added sugar intake will be divided into four centiles i.e., 25th percentile \[\<10.3g (2 tsps.)\], 50th percentile \[10.3-23.8g (2-5 tsps.)\], 75th percentile \[23.8-47.0g (5-9 tsps.)\] and 100th percentiles \[\>47g (9 tsps.)\].

Secondary

MeasureTime frameDescription
Study 1: Blood pressure8 weeksChange from baseline in blood pressure in mmHg at 8th weeks.
Study 1: Lipid profile8 weeksChange from baseline in total cholesterol, HDL-cholesterol, LDL-cholesterol and triglycerides in mmol/L at 8th weeks.
Study 1: Glucose profile8 weeksChange from baseline in fasting glucose in mmol/L at 8th weeks.
Study 1: Anthropometric measurements (height)8 weeksChange from baseline in height in meters at 8th weeks.
Study 1: Anthropometric measurements (weight)8 weeksChange from baseline in weight in kilograms at 8th weeks.
Study 1: Anthropometric measurements (waist circumference)8 weeksChange from baseline in waist circumference in centimeters at 8th weeks.
Study 1: Anthropometric measurements (hip circumference)8 weeksChange from baseline in hip circumference in centimeters at 8th weeks.
Study 1: Body mass index8 weeksWeight (kg) and height (m) will be combined to report body mass index in kg/m2.
Study 1: Waist hip ratio8 weeksWaist (cm) and hip circumference (cm) will be combined to report waist hip ratio
Study 1: Change from baseline in sugar consumption at 8th weeks8 weeksDietary sugar intake will be determined using a 3-day food record and semi-quantitative FFQ of added sugar intake. Total sugar (grams per day) in foods will be calculated using formula \[(total sugar (grams) - natural sugar (grams)\]. The total added sugar intake will be divided into four centiles i.e., 25th percentile \[\<10.3g (2 tsps.)\], 50th percentile \[10.3-23.8g (2-5 tsps.)\], 75th percentile \[23.8-47.0g (5-9 tsps.)\] and 100th percentiles \[\>47g (9 tsps.)\].
Study 1: Change from baseline in physical activity level at 8th weeks8 weeks\- Physical activity level will be measured using International Physical Activity Questionnaire (IPAQ) and results will be categorized as low, moderate and high physical activity.
Study 1: Change from baseline in intensity of physical activity at 8th weeks8 weeksMetabolic Equivalent Task (minutes/week) will be used to assess the intensity of physical activity.
Study 2: Change from baseline in anthropometric measurements (height)3 monthsHeight in meters will be taken.
Study 2: Change from baseline in anthropometric measurements (weight)3 monthsWeight in meters will be taken.
Study 2: Change from baseline in anthropometric measurements (waist circumference)3 monthsWaist circumference in centimeters will be taken.
Study 2: Change from baseline in anthropometric measurements (hip circumference)3 monthsHip circumference in centimeters will be taken.
Study 2: Change from baseline in body mass index3 monthsWeight (kg) and height (m) will be combined to report body mass index in kg/m2.
Study 2: Change from baseline in waist hip ratio3 monthsWaist (cm) and hip circumference (cm) will be combined to report waist hip ratio.
Study 2: Change from baseline in blood pressure3 monthsBlood pressure in mmHg will be taken.
Study 1: Inflammation biomarkers (interleukin-6)8 weeksChange from baseline in interleukin-6 in micrograms at 8th weeks.
Study 2: Change from baseline in sugar profile3 monthsFasting glucose in mmol/L will be measured.
Study 2: Change from baseline in antioxidant activity3 monthsAntioxidant activity in mmol/L will be measured.
Study 2: Change from baseline in 24-hour urinary sucrose/fructose3 monthsUrinary sucrose (mg/day) and fructose (mg/day) will be combined to report 24-hour urinary sucrose/fructose.
Study 2: Change from baseline in knowledge level3 monthsKnowledge level of healthy diet and sugar will be tested using Knowledge Assessment Questionnaire. The score will be presented in percentage.
Study 2: Change from baseline in health belief3 monthsHealth belief model construct will be determined using Health Belief Model questionnaire. Five subscales: perceived susceptibility, perceived severity, perceived benefits, perceived barriers and perceived self-efficacy will be measured and the scores will be presented in percentage.
Study 2: Change from baseline in mental health3 monthsMental health status will be measured using DASS-21 questionnaire, measuring depression (normal cut-off point: 0-4), anxiety (normal cut-off point: 0-3) and stress (normal cut-off point: 0-7).
Study 2: Change from baseline in physical activity level3 monthsPhysical activity level will be measured using International Physical Activity Questionnaire (IPAQ) and results will be categorized as low, moderate and high physical activity.
Study 2: Change from baseline in intensity of physical activity3 monthsMetabolic Equivalent Task (minutes/week) will be used to assess the intensity of physical activity.
Study 2: Change from baseline in lipid profile3 monthsTotal cholesterol, HDL-cholesterol, LDL-cholesterol and triglycerides in mmol/L will be measured.
Study 1: Inflammation biomarkers (TNF-α)8 weeksChange from baseline in TNF-α in picograms per milliliter at 8th weeks.
Study 1: Inflammation biomarkers (CPR)8 weeksChange from baseline in CPR in milligram per liter at 8th weeks.
Study 1: Oxidative stress biomarkers (MDA)8 weeksChange from baseline in MDA in millimolar at 8th weeks.
Study 1: Oxidative stress biomarkers (SOD)8 weeksChange from baseline in SOD in Units per milliliter at 8th weeks.
Study 1: Oxidative stress biomarkers (CAT)8 weeksChange from baseline in CAT in nanomoles at 8th weeks.
Study 1: TAC8 weeksChange from baseline in TAC in millimolar at 8th weeks.

Countries

Malaysia

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026